Search
According to the latest Precedence Research report, the global biotechnology market size is expected to grow from $1.77 trillion in 2025 to $6.34 trillion by 2035, at a compound annual growth rate of 13.61%. AI-driven drug discovery, gene editing, and advanced biologics are becoming core growth engines.
In 2026, the biotechnology sector is moving from promise to execution. AI-driven R&D, breakthroughs in gene editing, regulatory reforms, and global transactions are reshaping the life sciences landscape. This article examines 26 key trends, covering dimensions such as scientific innovation, emerging markets, policy changes, and business models.
In 2026, the biotech and life sciences industry reaches a critical turning point. From AI-driven drug discovery to clinical breakthroughs in gene editing, from regulatory reforms to global capital flows, these 26 trends are reshaping the future of medical innovation.
In 2026, the biotech and life sciences field reaches a critical turning point. AI and machine learning become R&D infrastructure, gene editing, synthetic biology, and microbiome therapies move toward clinical application, and global regulatory frameworks are being rapidly restructured. This article outlines 26 major trends, analyzing how technology, markets, capital, and policy are reshaping the healthcare innovation ecosystem.
This article reviews the important developments in the global medical technology sector during the third week of April 2025, covering financing, FDA approvals, clinical trials, and M&A collaborations, and analyzes the impact of technological trends such as neural interfaces, AI-assisted diagnosis, and leadless pacing on the industry.
According to a sharing by Public Intelligence CEO Peter Julius on HIMSS TV, early trials of the social robot Hana-chan have shown that it can enhance patients' emotional well-being and help aggressive patients relax. This article analyzes the significance of this progress for the healthcare technology industry, the affected companies, and future trends.
Siemens Healthineers is partnering with AiM Medical Robotics to integrate MRI scanning with a neurosurgical robotic platform; meanwhile, Procept BioRobotics has completed enrollment in a randomized study on prostate cancer. Together, these two developments point to a trend: medical device companies are accelerating their entry into more high-barrier treatment settings through image guidance, robotic systems, and clinical trials.